{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:15:26Z","timestamp":1794006926639,"version":"4.8.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2019.00321","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:32:00Z","timestamp":1558398720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":85,"title":["The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome"],"prefix":"10.3389","volume":"10","author":[{"given":"Mattia","family":"Barbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","article-title":"Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study","volume":"4","author":"Clayton","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000443861","article-title":"Cushing's syndrome: where and how to find it","volume":"46","author":"Debono","year":"2016","journal-title":"Front Horm Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/EJE-11-0272","article-title":"The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics","volume":"165","author":"Valassi","year":"2011","journal-title":"Eur J Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s12020-018-1709-y","article-title":"Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's","volume":"62","author":"Hirsch","year":"2018","journal-title":"Endocrine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/cen.12299","article-title":"Diagnosis and complications of Cushing's disease: gender-related differences","volume":"80","author":"Zilio","year":"2014","journal-title":"Clin Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1210\/jc.2002-021518","article-title":"Gender-related differences in the presentation and course of Cushing's disease","volume":"88","author":"Pecori Giraldi","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1055\/s-2007-992813","article-title":"Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure","volume":"39","author":"Pecori Giraldi","year":"2007","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab."},{"key":"B10","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s12020-016-0914-9","article-title":"The degree of urinary hypercortisolism is not correlated with the severity of cushing's syndrome","volume":"55","author":"Guarnotta","year":"2017","journal-title":"Endocrine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1210\/jc.2008-2694","article-title":"Blood pressure in pediatric patients with Cushing syndrome","volume":"94","author":"Lodish","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00431-016-2727-5","article-title":"Management of Cushing syndrome in children and adolescents: experience of a single tertiary centre","volume":"175","author":"G\u00fcemes","year":"2016","journal-title":"Eur J Pediatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.beem.2006.07.006","article-title":"Hypertension in Cushing's syndrome","volume":"20","author":"Magiakou","year":"2006","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1046\/j.1523-1755.2000.00978.x","article-title":"Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation","volume":"57","author":"Ferrari","year":"2000","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1210\/jc.2003-030138","article-title":"Hypertension and the cortisol-cortisone shuttle","volume":"88","author":"Quinkler","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11906-004-0046-0","article-title":"Glucocorticoid excess and hypertension","volume":"6","author":"Baid","year":"2004","journal-title":"Curr Hypertens Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1161\/HYPERTENSIONAHA.109.134973","article-title":"Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome","volume":"54","author":"Bailey","year":"2009","journal-title":"Hypertension."},{"key":"B19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1471-4892(01)00022-4","article-title":"Recent studies with eplerenone, a novel selective aldosterone receptor antagonist","volume":"1","author":"McMahon","year":"2001","journal-title":"Curr Opin Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J Clin Endocrinol Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/oby.2008.218","article-title":"11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity","volume":"16","author":"M\u00fcssig","year":"2008","journal-title":"Obes Silver Spring Md"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1210\/jc.2018-00065","article-title":"Increased urinary extracellular vesicle sodium transporters in Cushing syndrome with hypertension","volume":"103","author":"Salih","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000314315","article-title":"Hypertension in Cushing's syndrome: from pathogenesis to treatment","volume":"92","author":"Cicala","year":"2010","journal-title":"Neuroendocrinology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1530\/eje.0.1490549","article-title":"Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome","volume":"149","author":"Kirilov","year":"2003","journal-title":"Eur J Endocrinol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/HJH.0000000000000415","article-title":"The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications","volume":"33","author":"Isidori","year":"2015","journal-title":"J Hypertens."},{"key":"B26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1440-1797.2003.00215.x","article-title":"Glucocorticoids and the kidney","volume":"8","author":"Mangos","year":"2003","journal-title":"Nephrol Carlton Vic."},{"key":"B27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF03401535","article-title":"Pathogenesis of vascular complications in Cushing's syndrome","volume":"11","author":"Miljic","year":"2012","journal-title":"Horm Athens Greece."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1210\/jcem.86.12.8106","article-title":"The importance of adrenocortical glucocorticoids for adrenomedullary and physiological response to stress: a study in isolated glucocorticoid deficiency","volume":"86","author":"Zuckerman-Levin","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1161\/01.HYP.19.6.567","article-title":"Pressor responsiveness in corticosteroid-induced hypertension in humans","volume":"19","author":"Pirpiris","year":"1992","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","first-page":"GP203","DOI":"10.1530\/endoabs.56.GP203","article-title":"Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission","volume":"56","author":"Schernthaner-Reiter","year":"2018","journal-title":"Endocrine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000486002","article-title":"Metabolic syndrome in Cushing's syndrome patients","volume":"49","author":"Ferra\u00f9","year":"2018","journal-title":"Front Horm Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1210\/jcem.84.8.5896","article-title":"Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s11906-005-0013-4","article-title":"Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management","volume":"7","author":"Sacerdote","year":"2005","journal-title":"Curr Hypertens Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/LBR.0000000000000060","article-title":"Unusual triad of obstructive sleep apnea, uncontrolled hypertension, and severe hypokalemia due to ectopic adrenocorticotropic secretion","volume":"21","author":"Venkatram","year":"2014","journal-title":"J Bronchol Interv Pulmonol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1097\/HJH.0b013e328350e53b","article-title":"Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European Cost (cooperation in Scientific and Technological research) Action B26 on Obstructive Sleep Apnea","volume":"30","author":"Parati","year":"2012","journal-title":"J Hypertens."},{"key":"B36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jash.2014.05.007","article-title":"An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension","volume":"8","author":"Mirhafez","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"B37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000330416","article-title":"Adipokines and cardiovascular risk in Cushing's syndrome","volume":"95","author":"Valassi","year":"2012","journal-title":"Neuroendocrinology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/MNH.0000000000000385","article-title":"Renal effects of cytokines in hypertension","volume":"27","author":"Wen","year":"2018","journal-title":"Curr Opin Nephrol Hypertens."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens."},{"key":"B40","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1530\/EJE-16-0689","article-title":"Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry","volume":"176","author":"Berr","year":"2017","journal-title":"Eur J Endocrinol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.CIR.0000039288.86470.DD","article-title":"Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial","volume":"106","author":"Zanchetti","year":"2002","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet Lond Engl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"B44","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","article-title":"Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome","volume":"59","author":"Ayers","year":"2012","journal-title":"Hypertension"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1210\/jc.2002-021494","article-title":"Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure","volume":"88","author":"Faggiano","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"key":"B46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrneph.2016.101","article-title":"Idiopathic hypercalciuria and formation of calcium renal stones","volume":"12","author":"Coe","year":"2016","journal-title":"Nat Rev Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/S0002-9629(15)40676-7","article-title":"Diuretic complications","volume":"319","author":"Greenberg","year":"2000","journal-title":"Am J Med Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1097\/01.hjh.0000177537.91527.09","article-title":"The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension","volume":"23","author":"Mason","year":"2005","journal-title":"J Hypertens."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamainternmed.2018.1652","article-title":"Association of hydrochlorothiazide use and risk of malignant melanoma","volume":"178","author":"Potteg\u00e5rd","year":"2018","journal-title":"JAMA Intern Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"B52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/CIRCULATIONAHA.107.737957","article-title":"Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"118","author":"Chapman","year":"2008","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1097\/HJH.0b013e328339f9fa","article-title":"Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice","volume":"28","author":"Corrao","year":"2010","journal-title":"J Hypertens."},{"key":"B54","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/HYPERTENSIONAHA.109.139816","article-title":"Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis","volume":"55","author":"Gupta","year":"2010","journal-title":"Hypertension"},{"key":"B55","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/13543784.2010.495943","article-title":"Pasireotide for the treatment of Cushing's disease","volume":"19","author":"Arnaldi","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11102-014-0557-x","article-title":"Salivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing's disease","volume":"18","author":"Trementino","year":"2015","journal-title":"Pituitary."},{"key":"B58","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12020-014-0499-0","article-title":"The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study","volume":"50","author":"Trementino","year":"2015","journal-title":"Endocrine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12020-018-1669-2.","article-title":"Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease","volume":"62","author":"Barbot","year":"2018","journal-title":"Endocrine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"key":"B63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing's disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing's disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1038\/sj.jhh.1000987","article-title":"Dopamine: a role in the pathogenesis and treatment of hypertension","volume":"14","author":"Murphy","year":"2000","journal-title":"J Hum Hypertens."},{"key":"B66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing's syndrome","volume":"7","author":"Feelders","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1530\/EJE-07-0514","article-title":"Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease","volume":"158","author":"Castinetti","year":"2008","journal-title":"Eur J Endocrinol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1365-2796.1993.tb01018.x","article-title":"Response of hypertension to conventional antihypertensive treatment and\/or steroidogenesis inhibitors in Cushing's syndrome","volume":"234","author":"Fallo","year":"1993","journal-title":"J Intern Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bmj.2.6081.215","article-title":"Metyrapone in long-term management of Cushing's disease","volume":"2","author":"Jeffcoate","year":"1977","journal-title":"Br Med J."},{"key":"B71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1365-2265.2012.04424.x","article-title":"A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome","volume":"77","author":"Valassi","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing's syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine."},{"key":"B74","doi-asserted-by":"publisher","first-page":"P14","DOI":"10.1530\/endoabs.56.P14","article-title":"Preoperative treatment with metyrapone in patients with cushing's syndrome due to adrenal adenoma","volume":"56","author":"Puglisi","year":"2018","journal-title":"Endocr Connect."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"B77","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"B78","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/EJE-13-0477","article-title":"Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy","volume":"170","author":"van der Pas","year":"2014","journal-title":"Eur J Endocrinol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"key":"B80","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/nm784","article-title":"Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas","volume":"8","author":"Heaney","year":"2002","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1172\/JCI200316575","article-title":"PPAR-gamma receptor ligands: novel therapy for pituitary adenomas","volume":"111","author":"Heaney","year":"2003","journal-title":"J Clin Invest."},{"key":"B83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1046\/j.1463-1326.1999.00020.x","article-title":"Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study","volume":"1","author":"Patel","year":"1999","journal-title":"Diabetes Obes Metab."},{"key":"B84","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1530\/eje.0.1510173","article-title":"Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease","volume":"151","author":"Ambrosi","year":"2004","journal-title":"Eur J Endocrinol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2265.2005.02285.x","article-title":"Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease","volume":"63","author":"Cannav\u00f2","year":"2005","journal-title":"Clin Endocrinol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","article-title":"Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease","volume":"64","author":"Pecori Giraldi","year":"2006","journal-title":"Clin Endocrinol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1161\/HYPERTENSIONAHA.109.138883","article-title":"Losartan metabolite EXP3179: an AT1-receptor-independent treatment strategy for patients with the metabolic syndrome?","volume":"54","author":"Rossi","year":"2009","journal-title":"Hypertension"},{"key":"B88","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center","volume":"167","author":"Baudry","year":"2012","journal-title":"Eur J Endocrinol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-12-0368","article-title":"Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells","volume":"20","author":"Hescot","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1172\/JCI11098","article-title":"Retinoic acid prevents experimental Cushing syndrome","volume":"108","author":"P\u00e1ez-Pereda","year":"2001","journal-title":"J Clin Invest."},{"key":"B93","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1210\/jc.2012-2328","article-title":"Potential role for retinoic acid in patients with Cushing's disease","volume":"97","author":"Pecori Giraldi","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"8173182","DOI":"10.1155\/2016\/8173182","article-title":"The role of isotretinoin therapy for cushing's disease: results of a prospective study","volume":"2016","author":"Vilar","year":"2016","journal-title":"Int J Endocrinol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/j.1460-2075.1984.tb01879.x","article-title":"DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486","volume":"3","author":"Bourgeois","year":"1984","journal-title":"EMBO J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000314224","article-title":"Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone","volume":"92","author":"Castinetti","year":"2010","journal-title":"Neuroendocrinology."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"key":"B98","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/s-2004-835369","article-title":"Cortisol, 11beta-hydroxysteroid dehydrogenases, and hypertension","volume":"4","author":"van Uum","year":"2004","journal-title":"Semin Vasc Med."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00321\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:32:02Z","timestamp":1558398722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2019.00321\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":98,"alternative-id":["10.3389\/fendo.2019.00321"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2019.00321","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"article-number":"321"}}